2-氯-3-甲基苯并(b)噻吩 | 3216-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 2-氯-3-甲基苯并(b)噻吩
• 中文别名: 2-氯-3-甲基苯并(B)噻吩
• 英文名称: 3-chloromethylbenzothiophene
• 英文别名: 3-(Chloromethyl)benzo[b]thiophene；3-(chloromethyl)-1-benzothiophene
• CAS: 3216-47-5
• 化学式: C₉H₇ClS
• 分子量: 182.674
• InChiKey: JIXGRXJTSCZWNB-UHFFFAOYSA-N

物化性质

• 熔点：
  40 °C
• 沸点：
  129-131 °C(Press: 5.0 Torr)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氯-3-甲基苯并(b)噻吩 在 lithium aluminium tetrahydride 、 苄基三乙基氯化铵 作用下， 以 氘代四氢呋喃 、 水 为溶剂， 生成 2-(苯并[b]噻吩-3-基)乙胺
  参考文献：
  名称：

  D 1-样受体，可区分硫杂a​​嗪区域异构体

  摘要：

  由于受体螺旋内的高度同一性，设计具有D 1 / D 5亚型选择性的配体是一项挑战。基于先导化合物1-3，合成了噻吩-苯并ze庚因区域异构体4和5，并使用放射性配体结合亲和力技术对它们对五种多巴胺受体亚型的亲和力进行了生物学评估。内的d 1样家族，化合物4显示出对d 20倍的选择性5亚型超过d 1亚型（ķ我= 3nm时，d 1：60纳米），而它的区域异构体，化合物5用颠倒噻吩位置，更喜欢d 1在d亚型5亚型（ķ我= 4nM的，d 5：15纳米）。苯并噻吩并-苯并ze庚因类似物6被证明是对D 1-和D 2-样家族成员具有相同亲和力的几个数量级（A D 2和1.9的K i = 1.5 nM）具有高亲和力的a嗪衍生物之一。D 5为nM ）。彻底分析构成目标多巴胺受体亚型结合口袋的氨基酸残基，发现在D 5 通过阴离子氨基酸稳定的丝氨酸S 6.62和苏氨酸T 7.33残基或水网络的受体可能有助于合成化合物的选择性模式。

  DOI：

  10.1039/c5md00258c
• 作为产物：
  描述：

  3-甲醛苯并噻吩 在 sodium tetrahydroborate 、 氯化亚砜 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 3.63h， 生成 2-氯-3-甲基苯并(b)噻吩
  参考文献：
  名称：

  Simplifying Nickel(0) Catalysis: An Air-Stable Nickel Precatalyst for the Internally Selective Benzylation of Terminal Alkenes

  摘要：

  The synthesis and characterization of the air-stable nickel(II) complex trans-(PCy2Ph)(2)Ni(o-tolyl)Cl is described in conjunction with an investigation of its use for the Mizoroki-Heck-type, room temperature, internally selective coupling of substituted benzyl chlorides with terminal alkenes. This reaction, which employs a terminal alkene as an alkenylmetal equivalent, provides rapid, convergent access to substituted allylbenzene derivatives in high yield and with regioselectivity greater than 95:5 in nearly all cases. The reaction is operationally simple, can be carried out on the benchtop with no purification or degassing of solvents or reagents, and requires no exclusion of air or water during setup. Synthesis of the precatalyst is accomplished through a straightforward procedure that employs inexpensive, commercially available reagents, requires no purification steps, and proceeds in high yield.

  DOI：

  10.1021/ja3116718

文献信息

• IDO inhibitors
  申请人：Mautino Mario

  公开号：US10047066B2

  公开（公告）日：2018-08-14

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供的方法包括：(a) 调节吲哚胺2,3-二氧化酶的活性，包括将吲哚胺2,3-二氧化酶与本文描述的某一方面中描述的化合物的调节有效量接触；(b) 治疗需要吲哚胺2,3-二氧化酶（IDO）介导的免疫抑制的受试者，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(c) 治疗受益于吲哚胺-2,3-二氧化酶酶活性抑制的医疗状况，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；(d) 增强抗癌治疗的有效性，包括给予抗癌药物和本文描述的某一方面中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量；以及(f) 治疗与传染病相关的免疫抑制，例如HIV-I感染，包括给予本文描述的某一方面中描述的化合物的有效吲哚胺2,3-二氧化酶抑制量。
• Inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals Incorporated.

  公开号：US20040122000A1

  公开（公告）日：2004-06-24

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一类新型磺胺类化合物，其为天冬氨酸蛋白酶抑制剂。在一个实施例中，本发明涉及一类新型HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此，可以有利地用作抗HIV-1和HIV-2病毒的抗病毒剂。本发明还涉及使用本发明的化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。
• CCK or gastrin modulating benzo \x9bb!\x9b1,4! diazepines derivatives
  申请人：Glaxo Wellcome Inc.

  公开号：US05859007A1

  公开（公告）日：1999-01-12

  Benzo\x9bb!\x9b1,4!diazepine compounds of formula (I), where R.sup.1 is selected from C.sub.1 C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl, phenyl, or substituted phenyl; R.sup.2 is selected from C.sub.3 -C.sub.6 alkyl, C.sub.3 C.sub.6 cycloalkyl, C.sub.3 -C.sub.6 alkenyl, benzyl, phenylC.sub.1 -C.sub.3 alkyl of substituted phenyl; or NR.sup.1 R.sup.2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C.sub.1-6 alkyl C.sub.1-6 alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R.sup.3, R.sup.5, and R.sup.6 are independently hydrogen or C.sub.1-6 alkyl; R.sup.4 is C.sub.1-6 alkyl or C.sub.1-6 alkenyl; R.sup.7 is selected from the group consisting of hydrogen, C.sub.1-6 alkyl, C.sub.1-6 cycloalkyl, C.sub.1-6 alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR.sup.6 R.sup.7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R.sup.8 and R.sup.9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).

  以下是您提供的化学公式和描述的中文翻译： 本专利涉及1,4-苯并二氮杂卓化合物，其分子式为(I)，其中R1选自C1-C6烷基、C3-C6环烷基、苯基或取代苯基；R2选自C3-C6烷基、C3-C6环烷基、C3-C6烯基、苄基、苯基C1-C3烷基或取代苯基；或NR1R2共同形成1,2,3,4-四氢喹啉或苯并氮卓环，且单独或同时以C1-6烷基、C1-6烷氧基或卤素取代基进行单、双或三取代；p为0或1的整数；q为0或1的整数；r为0或1的整数；t为0或1的整数，条件是当r为0时，t也为0；R3、R5和R6独立地为氢或C1-6烷基；R4为C1-6烷基或C1-6烯基；R7选自氢、C1-6烷基、C1-6环烷基、C1-6烯基、苯基、取代苯基、萘基、杂芳基、取代杂芳基、双环杂芳基或取代双环杂芳基；或NR6R7共同形成一个由1,2,3或4个N、S或O杂原子隔断的饱和的5,6或7元环，条件是任意两个O或S原子不得相互连接；m为0、1、2、3或4的整数；R8和R9选自多种取代基；Z为氢或卤素；本专利还包括新颖的中间体、用于治疗肥胖、胆囊淤滞、胰腺分泌障碍的药物组合物，以及用于治疗这些疾病的方法和制备公式(I)化合物的方法。
• PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES
  申请人：Abdel-Magid Ahmed

  公开号：US20090176996A1

  公开（公告）日：2009-07-09

  The present invention is directed to novel processes for the preparation of sulfamide derivatves, useful in the treatment of epilepsy and related disorders.

  本发明涉及一种新型用于制备磺胺酰胺衍生物的方法，该衍生物在治疗癫痫和相关疾病中具有用途。
• Thiophenol-Mediated 1,5-Hydrogen Atom Abstraction: Easy Access to Mono- and Bicyclic Compounds
  作者：Florent Beaufils、Fabrice Dénès、Barbara Becattini、Philippe Renaud、Kurt Schenk

  DOI：10.1002/adsc.200505211

  日期：2005.10

  method for cyclization of alkynes is described. The reaction cascade involves the intermolecular addition of a phenylthiyl radical to a terminal triple bond generating an alkenyl radical, followed by a 1,5-hydrogen atom transfer and a 5-exo-trig radical cyclization. This very efficient tin-free procedure allows one to prepare highly functionalized cyclopentane derivatives as well as fused bicyclic and

  描述了硫代苯酚介导的炔烃环化方法。反应级联反应涉及在分子间将苯基噻吩基分子间加成到末端三键上，从而产生烯基基团，然后进行1，5-氢原子转移和5- exo- trig自由基环化。这种非常有效的无锡程序使人们可以从容易获得的前体制备高度官能化的环戊烷衍生物以及稠合的双环和螺环化合物。在该环化过程中，将苯硫基部分掺入最终的环化产物中。这种功能化对于产品的进一步转化特别有吸引力。